Embrex and Shenzhen Neptunus announce joint project

Monday, 21 August, 2006

Embrex has delivered an Egg Remover system and an Inovoject system to Shenzhen Neptunus Interlong Bio-technique (SNI). These have been installed in SNI's human influenza vaccine manufacturing facility at High-Tech Industrial Park Guangming, Shenzhen.

The high-speed automated Egg Remover system identifies and removes infertile eggs and "early dead' embryos on days 9 to 11 of incubation.

The viable eggs then proceed for inoculation with the influenza virus using the Inovoject system, which injects eggs at a rate of approximately 30,000 eggs/hour.

The system is part of meeting the critical technical and regulatory needs of human flu vaccine producers in many countries, including a proprietary sanitation system which cleans needles after the injection of every egg, thus minimising cross-contamination between eggs.

The manufacturing facility, which has recently completed construction, is believed to be the largest and most advanced human influenza vaccine production facility in China.

Related News

Applications open for Elevate: Boosting women in STEM

Elevate will award up to 500 undergraduate and postgraduate scholarships to women in science,...

Beckman Coulter Life Sciences appoints Suzanne Foster as President

A seasoned executive, Foster brings more than 25 years of experience in the healthcare industry.

National biotech incubator announces $17m in project funding

CUREator supports and accelerates the development of Australian biotech innovations, and has...


  • All content Copyright © 2022 Westwick-Farrow Pty Ltd